Abstract
To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support. Randomized phase I/II multicenter four-level (cyclophosphamide: 1000-1200-1400-1600 mg/m2; doxorubicin: 55-60-65-70 mg/m2; etoposide: 375-450-525-600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18-60 years) with newly diagnosed aggressive non-Hodgkin's lymphoma. Dose-limiting toxicity was defined as thrombocytopenia <80,000/mm3 and leukocytopenia <2500/mm3 on days 16 (CHOEP-14) and 23 (CHOEP-21) or prolonged (>4 days) leukocytopenia (<1000/mm3) or thrombocytopenia (<20,000/mm3). One hundred and thirty-nine patients (high-CHOEP-14: 47, high-CHOEP-21: 92) were randomly allocated to the study. Maximal tolerated dose was level 2 for CHOEP-14 and level 4 for CHOEP-21. With a less favorable profile of patients in CHOEP-14, 4-year event-free survival was 47.9% after high-CHOEP-14 and 66.2% after high-CHOEP-21, 4-year overall survival 62.1% after high-CHOEP-14 and 73.4% after high-CHOEP-21, respectively. Significant dose escalations of CHOEP are possible with granulocyte colony-stimulating factor su...Continue Reading
References
Oct 1, 1976·Cancer·E M McKelveyT E Moon
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A ShippL N Shulman
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H TillyB Coiffier
Feb 26, 2004·Blood·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin's Lymphoma Study Group
May 2, 2006·The Lancet Oncology·Michael PfreundschuhUNKNOWN MabThera International Trial Group
Citations
Mar 2, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Matti AaproDidier Kamioner
Oct 13, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N SchmitzM Pfreundschuh
Jun 3, 2014·Theoretical Biology & Medical Modelling·Sibylle SchirmMarkus Scholz
Jul 10, 2014·Leukemia·K HohlochL Trümper
Jan 22, 2011·Leukemia & Lymphoma·Dorte TholstrupMogens Groenvold
Nov 9, 2007·International Journal of Laboratory Hematology·G FeldmannR Woitas
Dec 30, 2014·BMC Systems Biology·Sibylle SchirmMarkus Scholz
Jun 19, 2014·Blood·Niels MurawskiMichael Pfreundschuh
Jul 28, 2010·Blood·Norbert SchmitzMichael Pfreundschuh
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhard HeldMichael Pfreundschuh
Feb 7, 2017·Journal of Biopharmaceutical Statistics·Cody ChiuzanShing M Lee
May 15, 2009·Scandinavian Journal of Immunology·S J VedelS D Nielsen
Nov 6, 2017·Journal of Cancer Research and Clinical Oncology·Sibylle SchirmMarkus Scholz
Oct 16, 2016·International Journal of Clinical Oncology·Helen Ma, Maher Abdul-Hay
Oct 14, 2020·Journal of Medical Case Reports·Yudi XiongYunfeng Zhou
May 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N SchmitzM Pfreundschuh